uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
October 28, 2019 07:00 ET
|
uniQure Inc.
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
September 27, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Pricing of its Public Offering
September 05, 2019 20:39 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Proposed Public Offering
September 04, 2019 16:02 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
September 03, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
August 30, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Leadership Promotions and Executive Transition
August 20, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 20, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress
July 29, 2019 07:18 ET
|
uniQure Inc.
~ Presented 36 Weeks of Follow-up Data from Phase IIb Study of AMT-061 Demonstrating Sustained Increases in FIX Activity at up to 54% of Normal ~ ~ Continuing Patient Recruitment in HOPE-B Pivotal...
uniQure to Participate in Multiple Upcoming Industry Conferences
May 31, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
May 02, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...